SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Haddad, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haddad, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The SSRI discontinuation syndrome

Peter Haddad

Moorside, Trafford General Hospital, Manchester, UK

A characteristic selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome appears to exist. It is usually mild, commences within 1 week of stopping treatment, resolves spontaneously within 3 weeks, and consists of diverse physical and psychological symptoms, the commonest being dizziness, nausea, lethargy and headache. SSRI reinstatement leads to resolution within 48 h. A transient stage of serotonin dysregulation appears central to causation with pharmacokinetic and pharmacodynamic differences accounting for the variation in incidence between the SSRIs. Discontinuation reactions are clinically relevant due to the associated morbidity, the potential for misdiagnosis and inappropriate treatment and because they may impair future antidepressant compliance. To minimize incidence, SSRIs, like other antidepressants, should be withdrawn gradually Provisional diagnostic criteria for the SSRI discontinuation syndrome are proposed. Prospective studies are required to investigate the syndrome, particularly its effects on patient care.

Key Words: adverse drug reaction • diagnostic criteria • review • serotonin uptake inhibitors • substance withdrawal syndrome • withdrawal

Journal of Psychopharmacology, Vol. 12, No. 3, 305-313 (1998)
DOI: 10.1177/026988119801200311


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
G. Kotzalidis, E. de Pisa, B. Patrizi, V. Savoja, G. Ruberto, and P. Girardi
Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient
J Psychopharmacol, July 1, 2008; 22(5): 581 - 584.
[Abstract] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
P. M. Haddad and I. M. Anderson
Recognising and managing antidepressant discontinuation symptoms
Adv. Psychiatr. Treat., November 1, 2007; 13(6): 447 - 457.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
P. M. Haddad, B. R. Pal, P. Clarke, A. Wieck, and S. Sridhiran
Neonatal symptoms following maternal paroxetine treatment: Serotonin toxicity or paroxetine discontinuation syndrome?
J Psychopharmacol, September 1, 2005; 19(5): 554 - 557.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
D. J. Nutt
Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors
J Psychopharmacol, December 1, 2003; 17(4): 355 - 364.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
L. Tamam and N. Ozpoyraz
Discontinuation Symptoms Associated with Nefazodone
J Psychopharmacol, December 1, 2003; 17(4): 447 - 450.
[Abstract] [PDF]


Home page
Br. J. PsychiatryHome page
R. J. PORTER, P. GALLAGHER, J. M. THOMPSON, and A. H. YOUNG
Neurocognitive impairment in drug-free patients with major depressive disorder
The British Journal of Psychiatry, March 1, 2003; 182(3): 214 - 220.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. A. Jenike
A 45-Year-Old Woman With Obsessive-Compulsive Disorder
JAMA, April 25, 2001; 285(16): 2121 - 2128.
[Full Text] [PDF]


Home page
J PsychopharmacolHome page
P. M. Haddad, S. Devarajan, and S. M. Dursun
Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'
J Psychopharmacol, March 1, 2001; 15(2): 139 - 141.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
I. M. Anderson, D. J. Nutt, and J. F. W. Deakin
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
J Psychopharmacol, January 1, 2000; 14(1): 3 - 20.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
P. Haddad
Do antidepressants have any potential to cause addiction?
J Psychopharmacol, May 1, 1999; 13(3): 300 - 307.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
B. J. Stanford and S. C. Stanford
Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
J Psychopharmacol, May 1, 1999; 13(3): 313 - 317.
[Abstract] [PDF]



Advertisement